Indinavir | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Indinavir | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Indinavir | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
Indinavir | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
Indinavir | hsa00513 | Various types of N-glycan biosynthesis | 4.83E-02 | 1 | Q9NR34 | MAN1C1 | More | |
Indinavir | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Indinavir | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Indinavir | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Indinavir | hsa00600 | Sphingolipid metabolism | 3.76E-02 | 1 | P15289 | ARSA | More | |
Indinavir | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | |
Indinavir | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Indinavir | hsa00830 | Retinol metabolism | 3.93E-02 | 3 | P00352, Q9BPW9, O75911 | ALDH1A1, DHRS9, DHRS3 | More | |
Indinavir | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Indinavir | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Indinavir | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
Indinavir | hsa01522 | Endocrine resistance | 1.69E-02 | 3 | Q9UM47, P10415, Q13323 | NOTCH3, BCL2, BIK | More | |
Indinavir | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Indinavir | hsa03040 | Spliceosome | 1.46E-02 | 4 | P17844, P51991, P61978, P11142 | DDX5, HNRPA3, HNRPK, HSPA8 | More | |
Indinavir | hsa03430 | Mismatch repair | 4.38E-02 | 1 | P20585 | MSH3 | More | |
Indinavir | hsa04015 | Rap1 signaling pathway | 9.14E-03 | 2 | P06213, O00522 | INSR, KRIT1 | More | |
Indinavir | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | |
Indinavir | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | |
Indinavir | hsa04062 | Chemokine signaling pathway | 6.73E-03 | 9 | P25024, P09341, P47992, Q9UBD3, P07948, P63218, P50151, P43250, Q08881 | CXCR1, CXCL1, XCL1, XCL2, LYN, GNG5, GNG10, GRK6, ITK | More | |
Indinavir | hsa04064 | NF-kappa B signaling pathway | 7.62E-04 | 12 | P10415, P51617, O00463, P14778, Q04759, Q9UDY8, Q13077, P07948, P06239, P24522, P09341, Q06643 | BCL2, IRAK1, TRAF5, IL1R1, PRKCQ, MALT1, TRAF1, LYN, LCK, GADD45A, CXCL1, LTB | More | |
Indinavir | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
Indinavir | hsa04141 | Protein processing in endoplasmic reticulum | 1.91E-03 | 6 | P18848, Q15437, Q99941, P11142, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, HSPA8, HSP90AA1, SAR1A | More | |
Indinavir | hsa04151 | PI3K-Akt signaling pathway | 3.91E-03 | 7 | P62753, P27348, P07900, P22105, Q99941, P18848, O00141 | RPS6, YWHAQ, HSP90AA1, TNXB, CREBL1, ATF4, SGK | More | |
Indinavir | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
Indinavir | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Indinavir | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
Indinavir | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.46E-02 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Indinavir | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
Indinavir | hsa04392 | Hippo signaling pathway - multiple species | 3.01E-02 | 1 | Q6V0I7 | FAT4 | More | |
Indinavir | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
Indinavir | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
Indinavir | hsa04612 | Antigen processing and presentation | 1.75E-02 | 6 | P13765, P01730, P26715, P26717, Q13241, P01732 | HLA-DOB, CD4, KLRC1, KLRC2, KLRD1, CD8A | More | |
Indinavir | hsa04613 | Neutrophil extracellular trap formation | 1.02E-04 | 8 | P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Indinavir | hsa04640 | Hematopoietic cell lineage | 1.60E-04 | 10 | P13612, P14778, P27930, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, IL1R1, IL1R2, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | |
Indinavir | hsa04650 | Natural killer cell mediated cytotoxicity | 3.08E-03 | 8 | P06239, O60880, P20963, Q13241, P26718, O14931, P26717, P26715 | LCK, SH2D1A, CD247, KLRD1, KLRK1, NCR3, KLRC2, KLRC1 | More | |
Indinavir | hsa04657 | IL-17 signaling pathway | 3.31E-02 | 3 | P49841, P14780, P01375 | GSK3B, MMP9, TNF | More | |
Indinavir | hsa04658 | Th1 and Th2 cell differentiation | 2.44E-07 | 11 | Q04759, P07766, P20963, P09693, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | |
Indinavir | hsa04659 | Th17 cell differentiation | 4.63E-06 | 11 | Q04759, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | |
Indinavir | hsa04660 | T cell receptor signaling pathway | 8.91E-04 | 9 | Q04759, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239 | PRKCQ, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK | More | |
Indinavir | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | |
Indinavir | hsa04722 | Neurotrophin signaling pathway | 3.76E-02 | 3 | P51617, P10415, P0DP23 | IRAK1, BCL2, CALM1 | More | |
Indinavir | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Indinavir | hsa04728 | Dopaminergic synapse | 4.78E-02 | 3 | Q99941, P18848, Q13557 | CREBL1, ATF4, CAMK2D | More | |
Indinavir | hsa04740 | Olfactory transduction | 2.07E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
Indinavir | hsa04744 | Phototransduction | 2.27E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
Indinavir | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
Indinavir | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | |
Indinavir | hsa04912 | GnRH signaling pathway | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | |
Indinavir | hsa04913 | Ovarian steroidogenesis | 2.52E-02 | 1 | P06213 | INSR | More | |
Indinavir | hsa04915 | Estrogen signaling pathway | 2.75E-03 | 5 | Q99941, P18848, P51828, P07900, P11142 | CREBL1, ATF4, ADCY7, HSP90AA1, HSPA8 | More | |
Indinavir | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | |
Indinavir | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
Indinavir | hsa04923 | Regulation of lipolysis in adipocytes | 3.76E-02 | 1 | P06213 | INSR | More | |
Indinavir | hsa04925 | Aldosterone synthesis and secretion | 1.69E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Indinavir | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Indinavir | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | |
Indinavir | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Indinavir | hsa04930 | Type II diabetes mellitus | 3.14E-02 | 1 | P06213 | INSR | More | |
Indinavir | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
Indinavir | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | |
Indinavir | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | |
Indinavir | hsa04960 | Aldosterone-regulated sodium reabsorption | 3.14E-02 | 1 | P06213 | INSR | More | |
Indinavir | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
Indinavir | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
Indinavir | hsa04975 | Fat digestion and absorption | 4.83E-02 | 1 | O14494 | PLPP1 | More | |
Indinavir | hsa04976 | Bile secretion | 2.44E-02 | 2 | P22694, P08183 | PRKACB, ABCB1 | More | |
Indinavir | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.95E-02 | 2 | Q06055, O15020 | ATP5G2, SPTBN2 | More | |
Indinavir | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | |
Indinavir | hsa05031 | Amphetamine addiction | 6.41E-03 | 3 | Q13557, Q99941, P18848 | CAMK2D, CREBL1, ATF4 | More | |
Indinavir | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Indinavir | hsa05132 | Salmonella infection | 3.04E-03 | 6 | P51617, Q9UJU2, P10415, O75369, Q9BQS8, Q13509 | IRAK1, LEF1, BCL2, FLNB, FYCO1, TUBB3 | More | |
Indinavir | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
Indinavir | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Indinavir | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Indinavir | hsa05146 | Amoebiasis | 9.73E-03 | 6 | P09341, P14778, P27930, P05089, P12814, P08311 | CXCL1, IL1R1, IL1R2, ARG1, ACTN1, CTSG | More | |
Indinavir | hsa05152 | Tuberculosis | 2.90E-03 | 5 | P0DP23, P48382, P10415, Q9UDY8, P51617 | CALM1, RFX5, BCL2, MALT1, IRAK1 | More | |
Indinavir | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | |
Indinavir | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | |
Indinavir | hsa05170 | Human immunodeficiency virus 1 infection | 1.99E-02 | 5 | P62873, P0DP23, P51617, P10415, Q9Y6Q5 | GNB1, CALM1, IRAK1, BCL2, AP1M2 | More | |
Indinavir | hsa05200 | Pathways in cancer | 4.99E-02 | 7 | Q9UJU2, P14923, P10415, Q13077, P62873, Q9UM47, P0DP23 | LEF1, JUP, BCL2, TRAF1, GNB1, NOTCH3, CALM1 | More | |
Indinavir | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
Indinavir | hsa05203 | Viral carcinogenesis | 9.17E-05 | 10 | Q99941, P18848, P27348, Q13547, Q15283, P61978, P58876, P62807, Q16778, O60814 | CREBL1, ATF4, YWHAQ, HDAC1, RASA2, HNRPK, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Indinavir | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Indinavir | hsa05205 | Proteoglycans in cancer | 4.10E-02 | 4 | Q13009, Q12955, O75369, P08962 | TIAM1, ANK3, FLNB, CD63 | More | |
Indinavir | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.73E-03 | 6 | P07766, P20963, P09693, P06239, Q04759, P01730 | CD3E, CD247, CD3G, LCK, PRKCQ, CD4 | More | |
Indinavir | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Indinavir | hsa05332 | Graft-versus-host disease | 3.93E-02 | 3 | P13765, P26715, Q13241 | HLA-DOB, KLRC1, KLRD1 | More | |
Indinavir | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | |
Indinavir | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |